Under the deal, the chain’s pharmacists will be trained to make formal diagnoses, formulate differential diagnosis plans and conduct full clinical trials “quickly and safely,” Alitam announced Friday (Aug. 19).
MHRx will also act as “a career development platform for the entire pharmacy team,” it added.
Read more: ‘Superpharmacy’ group wins PharmaDoctor in ‘seven-figure’ deal
It is hoped this will reduce “the substantial burden” on other NHS services and help reduce waiting times for urgent and routine hospital treatments.
It comes less than a week after Alitam – which has more than 100 offices in the UK and Ireland – revealed it had agreed terms to merge with clinical services provider PharmaDoctor in an unspecified seven-figure deal.
“Opportunity” to be less dependent on NHS income
Alitam founder and CEO Feisal Nahaboo said, “I have a job to fundamentally help pharmacists see their future business in a very different way.”
Pharmacists now have “a real chance” to be “less dependent on NHS income,” he stressed. Instead, they should “focus on improving the health of the country through research and diagnosis services,” he advised.
Acquiring MHRx “was my first goal,” he said. “With this merger now underway, Alitam will provide pharmacists with all the medical specialists and training they need.”
Read more: CEO of ‘Super Pharmacy’ Explains Plans for Pharmacogenomics Service
Alitam’s acquisition strategy is “ambitious,” with plans for 10% organic growth over the next five years, he added.
While he claimed that Alitam “has the support of thousands of pharmacies”, he also acknowledged that “it will take time to put the infrastructure and staff in place to deliver the best medical services”.
But, he added, “MHRx and Pharmadoctor’s support teams are making this rollout much easier.”
“A formidable talent”
Following the recent merger agreements, MHRx founder and CEO Mohammed Harb and Pharmadoctor CEO Graham Thoms will both be appointed as directors of Alitam, Mr Nahaboo confirmed.
It comes after Alitam made a number of high profile appointments in recent months, with former director of the Avicenna group, Bharti Patel, taking on the role of director of the group in March, and Jamal Butt, the former head of the pharmacy’s pharmacy. Boots UK, who joined Alitam in March. July.
“After a year of continued engagement and negotiations, I am delighted to announce this lineup, which represents a formidable array of talent,” said Mr. Nahaboo.
Read more: CEO ‘Superpharmacy’: Sector cries out for private investment’
In January, Mr. Nahaboo unveiled an ambitious plan to create a chain of “super pharmacies” focused on disease prevention and clinical services.
Its £1 billion “Pharmacy of the Future” concept aims to bring together “a range of healthcare services under one roof” in 500 high street, “state-of-the-art wellness and medical centres” in the UK and Ireland .